Great Drugs, If You Could Just Get Patients to Take Them
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 29, 2023 Category: Cardiology Source Type: research
METTL3: a Potential New Target in the Treatment Strategy of Atherosclerosis?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 29, 2023 Category: Cardiology Source Type: research
Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial
ConclusionThe findings of the INVICTUS trial indicated that rivaroxaban was found to be inferior in efficacy to VKA. However, it is important to note that the primary outcome of the trial was driven by sudden death and death caused by mechanical pump failure. As a result, it is necessary to approach the data from this study with caution, and it would be inappropriate to draw parallel conclusions for other causes of valvular AF. Particularly, the perplexing issue of how rivaroxaban could have contributed to both pump failure and sudden cardiac death requires further explanation. Additional data regarding changes in he...
Source: Cardiovascular Drugs and Therapy - May 25, 2023 Category: Cardiology Source Type: research
Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome
ConclusionWe identified 30 circulating proteins as potential preventive targets for AF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 22, 2023 Category: Cardiology Source Type: research
Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review
AbstractPurpose of ReviewThe risk of cardiovascular complications due to SARS-CoV-2 are significantly increased within the first 6 months of the infection. Patients with COVID-19 have an increased risk of death, and there is evidence that many may experience a wide range of post-acute cardiovascular complications. Our work aims to provide an update on current clinical aspects of diagnosis and treatment of cardiovascular manifestations during acute and long-term COVID-19.Recent FindingsSARS-CoV-2 has been shown to be associated with increased incidence of cardiovascular complications such as myocardial injury, heart failure...
Source: Cardiovascular Drugs and Therapy - May 20, 2023 Category: Cardiology Source Type: research
Improving STEMI Reperfusion with Intracoronary Thrombolysis: A Way to “Go with the Flow”
Keypoints:It is unclear what role, if any, intracoronary thrombolysis plays in the management of ST-segment elevation myocardial infarction (STEMI) with primary percutaneous coronary intervention (PPCI).In this meta-analysis intracoronary thrombolysis-facilitated PPCI for STEMI was associated with improved outcomes compared to standard PPCI.A randomized controlled trial would be necessary to settle the question of whether intracoronary thrombolysis is a useful adjunct to PPCI and whether it is most effective before, during, or after PPCI. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 18, 2023 Category: Cardiology Source Type: research
Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential
ConclusionTargeting the immune-inflammatory response via Treg-based therapies might provide a promising and novel future approach to the prevention and treatment of pathological cardiac hypertrophy. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 15, 2023 Category: Cardiology Source Type: research
Research progress on the therapeutic effects of nanoparticles loaded with drugs against atherosclerosis
AbstractPresently, there are many drugs for the treatment of atherosclerosis (AS), among which lipid-lowering, anti-inflammatory, and antiproliferative drugs have been the most studied. These drugs have been shown to have inhibitory effects on the development of AS. Nanoparticles are suitable for AS treatment research due to their fine-tunable and modifiable properties. Compared with drug monotherapy, experimental results have proven that the effects of nanoparticle-encapsulated drugs are significantly enhanced. In addition to nanoparticles containing a single drug, there have been many studies on collaborative drug treatm...
Source: Cardiovascular Drugs and Therapy - May 13, 2023 Category: Cardiology Source Type: research
Development and Validation of a Nomogram Model Affecting the ACT Targeting Rate During Radiofrequency Ablation of Atrial Fibrillation in China
ConclusionThe nomogram model has good discrimination and accuracy, which can screen attainment groups intuitively and individually, and has a certain predictive value for the probability of ACT reaching the target after the adequate dosage of initial heparin in Chinese patients with atrial fibrillation. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 9, 2023 Category: Cardiology Source Type: research
Effect of Prolonged Use of Dronedarone on Recurrence in Patients with Non-Paroxysmal Atrial Fibrillation After Radiofrequency Ablation (DORIS): Rationale and Design of a Randomized Multicenter, Double-Blinded Placebo-Controlled Trial
ConclusionThis trial will evaluate whether prolonged use of dronedarone effectively reduces the recurrence rate after ablation in non-paroxysmal AF patients. The result of this trial will provide evidence for optimizing post-ablation anti-arrhythmic therapy.Trial registrationClinicalTrials.gov; NCT05655468, 19-December-2022 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 8, 2023 Category: Cardiology Source Type: research
Great Drugs, If You Could Just Get Patients to Take Them
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 6, 2023 Category: Cardiology Source Type: research
Glucagon-Like Peptide-1 Inhibits the Progression of Abdominal Aortic Aneurysm in Mice: The Earlier, the Better
ConclusionsThe GLP-1 receptor agonist liraglutide was found to inhibit AAA progression in mice by exerting anti-inflammatory and antioxidant effects, particularly during the early stages of AAA formation. Therefore, liraglutide may represent a potential pharmacological target for the treatment of AAA. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 5, 2023 Category: Cardiology Source Type: research
Targeted Mobilisation of Endogenous Endothelial Progenitor Cells — an Alternate Approach to Allogeneic Therapy for Ischaemic Cardiovasular Disease?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 3, 2023 Category: Cardiology Source Type: research
The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
ConclusionThis study showed for the first time the suitability of PCSK9ab treatment for reduction of platelet reactivity in FH patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 2, 2023 Category: Cardiology Source Type: research
